The company said it will discontinue clinical development of the drug in ulcerative colitis (UC).
The Origin phase 2a study demonstrated that GLPG1205 did not differentiate from the placebo on (partial) Mayo scores.
The drug was shown to be overall safe and well-tolerated by patients in the study. The exposure data was reported to be in line with healthy volunteer information from the earlier phase 1 clinical trial.
Galapagos said it will publish further details of the Origin study later this year. It will also examine whether GLPG1205 will be developed in other indications.
GLPG1205, works on GPR84, a novel mechanism of action developed by Galapagos for inflammatory bowel diseases (IBD).
GPR84 is a free fatty acid receptor which triggers the onset and aggravation of UC.
GLPG1205 was administered on patients during origin proof-of-concept phase 1 and 2 studies.
The phase 1 study involved oral administration of single and multiple ascending doses of GLPG1205, which showed a complete inhibition of GPR84 and favourable properties.
Galapagos is engaged in the discovery and development of small molecule medicines with novel modes of action.
The company’s pipeline includes three phase 2 programs, two phase 1 studies, five pre-clinical trials, and 20 discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications.